Serodiagnostic potential of Mycobacterium avium MAV2054 and MAV5183 proteins
- PMID: 23269416
- PMCID: PMC3571277
- DOI: 10.1128/CVI.00649-12
Serodiagnostic potential of Mycobacterium avium MAV2054 and MAV5183 proteins
Abstract
The Mycobacterium avium-M. intracellulare complex (MAC) causes a pulmonary disease (PD) similar to tuberculosis (TB). Diagnosis of MAC-PD is complicated and time-consuming. In this study, the serodiagnostic potential of the newly identified MAV2054 and MAV5183 proteins was evaluated in subjects with MAC-PD, pulmonary TB, or latent TB and in noninfected healthy controls (HC), together with HspX and the 38-kDa antigen, well-known serodiagnostic M. tuberculosis antigens. All four antigens evoked significantly higher IgG responses in MAC-PD and active TB than in latent TB and HC subjects. Among the antigens, MAV2054 elicited the highest antibody responses in pulmonary TB and MAC-PD patients. IgG titers against MAV2054 and MAV5183 were significantly higher in MAC-PD than in pulmonary TB subjects. In addition, the levels of IgG against all antigens in the M. intracellulare and fibrocavitary forms were higher than those in the M. avium and nodular bronchiectatic forms, respectively. Based on sensitivity and receiver operator characteristic curve analysis, the best candidates for detection of MAC-PD and pulmonary TB were MAV2054 and the 38-kDa antigen, respectively. In total, 76.0% of MAC-PD and 65.0% of active TB patients were reactive to at least two antigens. In contrast, only 2.8% of HC subjects were reactive with two or more antigens. Our findings suggest that an enzyme-linked immunosorbent assay (ELISA) using the four antigens would be valuable for screening for mycobacterial lung disease, including MAC-PD and pulmonary TB, although it does not provide good discrimination of the disease-causing pathogens.
Figures


Similar articles
-
Differences in serological responses to specific glycopeptidolipid-core and common lipid antigens in patients with pulmonary disease due to Mycobacterium tuberculosis and Mycobacterium avium complex.J Med Microbiol. 2006 Feb;55(Pt 2):189-199. doi: 10.1099/jmm.0.46087-0. J Med Microbiol. 2006. PMID: 16434712
-
Serodiagnosis of Mycobacterium avium-complex pulmonary disease with an enzyme immunoassay kit that detects anti-glycopeptidolipid core antigen IgA antibodies in patients with rheumatoid arthritis.Mod Rheumatol. 2011 Apr;21(2):144-9. doi: 10.1007/s10165-010-0368-5. Epub 2010 Nov 18. Mod Rheumatol. 2011. PMID: 21082209
-
Serological assay by use of glycopeptidolipid core antigen for Mycobacterium avium complex.Scand J Infect Dis. 2013 Apr;45(4):241-9. doi: 10.3109/00365548.2012.714904. Epub 2013 Feb 7. Scand J Infect Dis. 2013. PMID: 23387370
-
Serodiagnosis of Mycobacterium avium complex disease in humans: translational research from basic mycobacteriology to clinical medicine.Jpn J Infect Dis. 2014;67(5):329-32. doi: 10.7883/yoken.67.329. Jpn J Infect Dis. 2014. PMID: 25241680 Review.
-
Interrelational changes in the epidemiology and clinical features of nontuberculous mycobacterial pulmonary disease and tuberculosis in a referral hospital in Japan.Respir Med. 2019 Jun;152:74-80. doi: 10.1016/j.rmed.2019.05.001. Epub 2019 May 8. Respir Med. 2019. PMID: 31128614 Review.
Cited by
-
Effect and Mechanism of Mycobacterium avium MAV-5183 on Apoptosis of Mouse Ana-1 Macrophages.Cell Biochem Biophys. 2024 Jun;82(2):885-894. doi: 10.1007/s12013-024-01239-3. Epub 2024 Mar 2. Cell Biochem Biophys. 2024. PMID: 38430410
-
Highlight on advances in nontuberculous mycobacterial disease in North America.Biomed Res Int. 2014;2014:919474. doi: 10.1155/2014/919474. Epub 2014 Sep 11. Biomed Res Int. 2014. PMID: 25574470 Free PMC article. Review.
-
Genetic Involvement of Mycobacterium avium Complex in the Regulation and Manipulation of Innate Immune Functions of Host Cells.Int J Mol Sci. 2021 Mar 16;22(6):3011. doi: 10.3390/ijms22063011. Int J Mol Sci. 2021. PMID: 33809463 Free PMC article. Review.
-
Mycobacterium avium MAV2054 protein induces macrophage apoptosis by targeting mitochondria and reduces intracellular bacterial growth.Sci Rep. 2016 Nov 30;6:37804. doi: 10.1038/srep37804. Sci Rep. 2016. PMID: 27901051 Free PMC article.
References
-
- Herdman AV, Steele JC., Jr 2004. The new mycobacterial species—emerging or newly distinguished pathogens. Clin. Lab. Med. 24:651–690 - PubMed
-
- Falkinham JO, III, Iseman MD, de Haas P, van Soolingen D. 2008. Mycobacterium avium in a shower linked to pulmonary disease. J. Water Health 6:209–213 - PubMed
-
- Anonymous 1997Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am. J. Respir. Crit. Care Med. 156:S1–S25 - PubMed
-
- Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, Iseman M, Olivier K, Ruoss S, von Reyn CF, Wallace RJ, Jr, Winthrop K, on behalf of the ATS Mycobacterial Diseases Subcommittee 2007. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am. J. Respir. Crit. Care Med. 175:367–416 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources